Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing

Article excerpt

Eli Lilly is betting $3.8 billion on vaccine development, but the investment announcement has largely flown under investor radar. The pharma giant is wagering heavily on vaccines for diseases like RSV and cervical cancer, areas where traditional players like Merck and GSK have already scored wins. The big question: can Lilly, traditionally stronger in oncology and diabetes drugs, execute in vaccines fast enough to justify the spending? Analysts say the move signals Lilly's ambition to diversify beyond its blockbuster GLP-1 drugs, though vaccine development carries longer timelines and regulatory uncertainty.